leflunomide has been researched along with Polymyositis in 3 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Polymyositis: Diseases characterized by inflammation involving multiple muscles. This may occur as an acute or chronic condition associated with medication toxicity (DRUG TOXICITY); CONNECTIVE TISSUE DISEASES; infections; malignant NEOPLASMS; and other disorders. The term polymyositis is frequently used to refer to a specific clinical entity characterized by subacute or slowly progressing symmetrical weakness primarily affecting the proximal limb and trunk muscles. The illness may occur at any age, but is most frequent in the fourth to sixth decade of life. Weakness of pharyngeal and laryngeal muscles, interstitial lung disease, and inflammation of the myocardium may also occur. Muscle biopsy reveals widespread destruction of segments of muscle fibers and an inflammatory cellular response. (Adams et al., Principles of Neurology, 6th ed, pp1404-9)
| Excerpt | Relevance | Reference |
|---|---|---|
| " We treated a patient who developed polymyositis (PM) following the treatment of RA with leflunomide." | 7.75 | Leflunomide-induced polymyositis in a patient with rheumatoid arthritis. ( Nagashima, M; Ochi, S; Taniguchi, K, 2009) |
| "Leflunomide is a new immunosuppressive drug recently introduced in the treatment of rheumatoid and psoriatic arthritis." | 5.33 | Anti-Jo-1 antibody positive polymyositis--successful therapy with leflunomide. ( Lange, U; Müller-Ladner, U; Piegsa, M; Strunk, J, 2006) |
| " We treated a patient who developed polymyositis (PM) following the treatment of RA with leflunomide." | 3.75 | Leflunomide-induced polymyositis in a patient with rheumatoid arthritis. ( Nagashima, M; Ochi, S; Taniguchi, K, 2009) |
| "Leflunomide is a new immunosuppressive drug recently introduced in the treatment of rheumatoid and psoriatic arthritis." | 1.33 | Anti-Jo-1 antibody positive polymyositis--successful therapy with leflunomide. ( Lange, U; Müller-Ladner, U; Piegsa, M; Strunk, J, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ochi, S | 1 |
| Taniguchi, K | 1 |
| Nagashima, M | 1 |
| Luca, NJ | 1 |
| Atkinson, A | 1 |
| Hawkins, C | 1 |
| Feldman, BM | 1 |
| Lange, U | 1 |
| Piegsa, M | 1 |
| Müller-Ladner, U | 1 |
| Strunk, J | 1 |
3 other studies available for leflunomide and Polymyositis
| Article | Year |
|---|---|
Leflunomide-induced polymyositis in a patient with rheumatoid arthritis.
Topics: Adjuvants, Immunologic; Alanine Transaminase; Anti-Inflammatory Agents; Antirheumatic Agents; Arthri | 2009 |
Anti-signal recognition particle-positive juvenile polymyositis successfully treated with rituximab.
Topics: Antibodies, Monoclonal, Murine-Derived; Autoantibodies; Azathioprine; Child; Drug Therapy, Combinati | 2012 |
Anti-Jo-1 antibody positive polymyositis--successful therapy with leflunomide.
Topics: Antibodies, Antinuclear; Arthritis; Autoantibodies; Azathioprine; Drug Therapy, Combination; Female; | 2006 |